Dusigitumab clinical trials
Also written MEDI-573.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2009
How each study uses dusigitumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- MEDI-573
- 2
Studies by the year they started
3 studies that test it; most in 2009 (1)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2011 | 1 |
| 2012 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Studies
Open first, then newest update. How each study uses dusigitumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573 in Subjects With Advanced Solid TumorsCompletedPhase 1MedImmune LLCNCT00816361Written as MEDI-573
- MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.CompletedPhase 1MedImmune LLCNCT01498952Written as MEDI-573 (1 of 3 doses)
- Dose-escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MEDI-573 in Japanese SubjectsCompletedPhase 1AstraZenecaNCT01340040Written as MEDI-573
Given beside what is tested · 1 — dusigitumab is usual care or a partner of the new treatment
Codes
What other systems call dusigitumab · ClinicalTrials.gg INT000312
- MeSH (NLM) C000601324dusigitumabOne source NLM
- UNII (FDA) 0Z70DT5PRXDUSIGITUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q5316908DusigitumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C82683DusigitumabOne source FDA
- DrugBank DB12363One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000601324 | dusigitumab | One source NLM |
| UNII (FDA) | 0Z70DT5PRX | DUSIGITUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q5316908 | Dusigitumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C82683 | Dusigitumab | One source FDA |
| DrugBank | DB12363 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.